

New Collaboration Between Psifas and OpenDNA: Predicting Common Diseases Through AI and Genomic Data

HAIFA, ISRAEL, ISRAEL, June 3, 2025 /EINPresswire.com/ -- The Israeli National Initiative for Personalized Medicine, Psifas, and OpenDNA a Genomic AI biotech company have announced a strategic collaboration to develop artificial intelligence models that predict genetic risk for common diseases. The research will combine the power of Psifas's extensive genomic and clinical data with OpenDNA's advanced AI technologies.

The study will focus on developing 32 Polygenic Risk Score (PRS) models, including the following diseases:

- Cardiovascular disease
- Breast cancer
- Prostate cancer
- Colorectal cancer

All analysis will be performed in a secure, cloud-based research environment, in full compliance with ethical and privacy standards. As part of the agreement, the PRS results will be added back to the Psifas biobank, enriching the data available for future research and enabling benefit for both current and future volunteers.

Prof. Gabriel Barbash, Director of Psifas:

"Today, we treat diseases only after they've already caused harm – and that's far too late. One of Psifas's goals is to detect diseases during the silent incubation stage, when there's still a chance to stop them. This collaboration is an important step in that direction, combining Israeli high-quality clinical data with smart algorithms that help us predict who needs attention early."

Eran Feldhay, CEO of OpenDNA:

"This collaboration marks a significant milestone. The data provided by Psifas will empower our AI engine to deliver real-world, clinically-relevant disease preventing genomic insights that could ultimately save lives."

About Psifas

Psifas is Israel's national program for precision medicine, integrating genetic and clinical data to accelerate research and the development of personalized treatments.

<https://partnership.psifas.org.il/>

About OpenDNA

OpenDNA is an Israeli startup developing AI-powered genomic models to support personalized care and disease prevention through deep genetic analysis.

Eran Feldhay

OpenDNA

eran@open-dna.com

This press release can be viewed online at: <https://www.einpresswire.com/article/818578565>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.